home > ict > winter 2021 > the hundred-year quest
International Clinical Trials

The Hundred-Year Quest

Over 20 years after creating the Edmonton Protocol, a process celebrated as a possible ‘cure’ for diabetes, Dr James Shapiro is at it again. This time, using stem cells. The academic in Canada is researching a new possibility of engineering stem cells to become the insulin-producing islet cells found in the pancreas.

Dr Shapiro explains: “The biggest challenges with the Edmonton protocol approach, where we use cells taken from organ donors, are that we have to use organ donors. When we think about the enormous burden of diabetes worldwide, 463 million people with all forms of diabetes, it’s been clear all along that there would never be enough cells to go around to treat that kind of patient base if the organ donor approach became a therapy for all diabetes. The second, perhaps bigger, limitation is that those donor cells are allogeneic. In other words, they’re foreign to the body. Because of that, anti-rejection drugs have to be given just like any other organ transplant, like a heart, lung, or liver, or those cells will be rejected by the body. To overcome those two challenges, it became clear to us that stem cells provided a unique opportunity to fix both the supply problem and the anti-rejection problem.”

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
Born in Leeds, England, Professor James Shapiro obtained his MD at the University of Newcastle-upon-Tyne, UK, and trained in Surgery at the University of Bristol, UK. After joining the faculty at the University of Alberta, Canada, in 1998, Professor Shapiro led the clinical team with the ‘Edmonton Protocol’ islet transplant success, and was lead author on the 2000 NEJM study. He is a Canada Research Chair in Transplantation Surgery and Regenerative Medicine, and has been the recipient of multiple awards, including the Hunterian Medal from the Royal College of Surgeons of England, the Gold Medal in Surgery from the Governor General of Canada, Physician of the Century, and was recently named one of Nature Biotechnology's most remarkable and influential personalities.
Print this page
Send to a friend
Privacy statement
News and Press Releases


-- If Approved, KTE-X19 will be an Important New Advance for this Disease with a Poor Prognosis -- -- Kite would Become the First Company with Multiple Approved CAR T Therapies in Europe --
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

Industry Events

DIA Europe 2021

15-19 March 2021, VIRTUAL CONFERENCE

DIA Europe is the must-attend event for all life science professionals working in drug development, from discovery to marketed use. It encourages open collaboration by bringing together representatives from the entire spectrum of the life science landscape and facilitating crucial discussions across several topic tracks: Clinical Development, Regulatory Strategy, Pharmacovigilance, Value and Access, Health Policy, and many more.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement